NeOnc Technologies Holdings, Inc. (NTHI)
NTHI moved a median of -1.60% 30 minutes after news, and -1.14% by the close. How NTHI actually reacts to news — the realized, point-in-time move the market made, measured across 259 labeled events over the last three years with zero look-ahead.
NTHI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 27% | 226 |
| 30-min | -1.60% | 36% | 237 |
| 60-min | -1.73% | 37% | 243 |
| to close | -1.14% | 36% | 235 |
| Middle 50% of NTHI reactions | -4.99% to +1.13% |
|---|---|
| Median reaction (30-min) | -1.60% |
| Measured reactions | 259 |
Half of all NeOnc Technologies Holdings, Inc. news events land between -4.99% and +1.13% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when NTHI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NTHI's baseline. Nothing else.
Recent NTHI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K NEONC TECHNOLOGIES HOLDI For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach | Press release | GlobeNewswire | +0.00% | -1.41% | |
| NeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial | Press release | GlobeNewswire | -0.90% | +8.99% | |
| NeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations | Press release | GlobeNewswire | -0.21% | +3.41% | |
| FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track | Press release | GlobeNewswire | -1.34% | +0.89% | |
| NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100 | Press release | GlobeNewswire | -1.34% | +0.89% | |
| NeOnc CEO Amir Heshmatpour Adds 80,000 Shares in Open-Market Purchases | Press release | GlobeNewswire | +0.00% | +17.79% | |
| NeOnc CEO Adds Another 70,000 Shares as Insider Buying Continues | Press release | GlobeNewswire | -5.24% | -2.09% | |
| Form 10-Q NEONC TECHNOLOGIES HOLDI For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +2.56% | |
| Form 8-K NEONC TECHNOLOGIES HOLDI For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | +1.05% | +7.38% | |
| NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress | Press release | GlobeNewswire | +0.00% | +2.56% | |
| Form 8-K NEONC TECHNOLOGIES HOLDI For: Nov 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.64% | |
| NeOnc Is Putting Two Brain Cancer Programs on the Global Stage | Press release | GlobeNewswire | +0.65% | -0.81% | |
| NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology | Press release | GlobeNewswire | -0.62% | -4.66% | |
| NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage | Press release | GlobeNewswire | +0.00% | +3.17% | |
| NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries | Press release | GlobeNewswire | +10.70% | -13.76% | |
| NeOnc Breaks Through Key Levels, as Brain-Cancer Stock’s Catalysts Continue | Press release | GlobeNewswire | +0.23% | -6.03% | |
| Form 8-K NEONC TECHNOLOGIES HOLDI For: Oct 16 | SEC filing · Form 8-K | SEC EDGAR | -0.34% | +10.85% | |
| NeOnc Heads to Fox Business as Brain Cancer Milestones Put Its Mission in the Spotlight | Press release | GlobeNewswire | +0.00% | -1.67% | |
| NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy | Press release | GlobeNewswire | +0.00% | -1.67% | |
| Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market | Press release | GlobeNewswire | +2.23% | +3.71% | |
| NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward | Press release | GlobeNewswire | +2.12% | +3.55% | |
| NeOnc Technologies and the Department of Health – Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical Collaboration | Press release | GlobeNewswire | +0.03% | +3.57% | |
| Forget the Ugly Sweaters and Ugly Charts, NeOnc is Ready for Catalyst Season | Press release | GlobeNewswire | — | -0.18% | |
| NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi | Press release | GlobeNewswire | -1.79% | -3.57% | |
| NeOnc’s Boldest Test Yet: Child’s Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone | Press release | GlobeNewswire | -1.79% | -3.57% | |
| Form 8-K NEONC TECHNOLOGIES HOLDI For: Oct 09 | SEC filing · Form 8-K | SEC EDGAR | -1.79% | -3.57% | |
| NeOnc CEO Amir F. Heshmatpour to Address Global Life Sciences Investment at Abu Dhabi Future Health Summit 2026 | Press release | GlobeNewswire | +1.50% | +3.38% | |
| UAE Banking Heavyweight Joins NeOnc as Global Brain-Cancer Drug Development Advances | Press release | GlobeNewswire | +1.50% | +3.38% | |
| NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development | Press release | GlobeNewswire | +0.00% | -1.11% | |
| NeOnc Technologies Appoints Ali Alabedin to Its Board of Directors | Press release | GlobeNewswire | +1.34% | +1.53% | |
| NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer | Press release | GlobeNewswire | — | -6.55% | |
| NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt | Press release | GlobeNewswire | +0.00% | +1.36% | |
| NeOnc’s Powerful Brain Cancer Pipeline Advances | Press release | GlobeNewswire | -2.24% | -1.49% | |
| Form 8-K NEONC TECHNOLOGIES HOLDI For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | -2.24% | -1.49% | |
| NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212 | Press release | GlobeNewswire | +4.07% | -3.07% | |
| Powerful NeOnc Brain Cancer Pipeline Advances | Press release | GlobeNewswire | — | -2.17% | |
| NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst | Press release | GlobeNewswire | +0.00% | -2.22% | |
| NeOnc’s Delivery may Finally Change the Equation for Brain Cancer’s Next Frontier | Press release | GlobeNewswire | +0.58% | +0.58% | |
| Form 8-K NEONC TECHNOLOGIES HOLDI For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | +3.57% | +3.60% | |
| NeOnc Charting New Nasal Route to Treating Brain Cancer | Press release | GlobeNewswire | +1.51% | +0.91% | |
| Form 8-K NEONC TECHNOLOGIES HOLDI For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | +5.65% | +13.29% | |
| NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates | Press release | GlobeNewswire | +5.65% | +13.29% | |
| NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution | Press release | GlobeNewswire | +5.65% | +13.29% | |
| NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results | Press release | GlobeNewswire | -6.01% | -12.32% | |
| NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA | Press release | GlobeNewswire | -6.01% | -12.32% | |
| Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus | Press release | GlobeNewswire | — | -7.28% | |
| Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test | Press release | GlobeNewswire | +0.00% | -1.05% | |
| Form 8-K NEONC TECHNOLOGIES HOLDI For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | -1.35% | -1.48% | |
| NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data | Press release | GlobeNewswire | +2.12% | -3.98% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NTHI section they belong to.
Where else NTHI is measured.
NTHI earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is NeOnc Technologies Holdings, Inc.'s median reaction calculated?
Every labeled NTHI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 259 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 36% of NTHI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NTHI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.